Villepinte, 29 September 2015 - Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, announces the availability to the public and the filing of its 2015 Half-Yearly Financial Report with the French Autorité des Marchés Financiers (AMF).
This document is available on Guerbet's website at www.guerbet.com in Investors - Documents section.
About Guerbet
Guerbet is a pioneer in the contrast agent field, with nearly 90 years' experience, and is the only pharmaceutical group dedicated to medical imaging worldwide. It offers a comprehensive range of X-Ray, Magnetic Resonance Imaging (MRI) and Interventional Radiology and Theranostics (IRT) products, along with a range of injectors and related medical devices to improve the diagnosis and treatment of patients. To discover new products and ensure future growth, Guerbet invests heavily in R&D, spending around 9% of its sales each year. Guerbet (GBT) is listed on NYSE Euronext Paris (Segment B - Mid Caps) and generated revenue of €409 million in 2014. It had a total workforce of 1,461 employees at 31 December 2014.
For more information about Guerbet, please visit www.guerbet.com
